News Sentiment

ADAG sentiment intelligence

Adagene Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 52 Balanced news tone 50 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 3.94 Week of 10 Jul 2026
Weighted tone 52/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

76/100 classification confidence.

Company focus 42

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend active

-11.9% over one week, +10.4% over four weeks, trend active, and materially above fair value.

Latest direct headline Positive

Guggenheim reiterates Adagene stock Buy rating on competitor shift

Market Reaction

Price moving ahead of tone

59/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 76/100 classification
One-week reaction -11.9% Price reacting lower
Trend fit Trend active 10.4% over four weeks
Fair value 68.2% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 12
Neutral 28
Negative 10

Relevance

Why the article matched

Direct first
Direct company coverage 42
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 8
TradingView 8
TradingKey 5
dars.gov.et 4
GlobeNewswire 4
Quartr 3
Stock Titan 3
DonanımHaber 3

Event Lens

What the news is about

Classified themes
Market update 21
Earnings 20
Analyst action 5
Balance sheet 1
Capital return 1
Deals and strategy 1
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 50
Investing.com Nigeria Direct company coverage

Guggenheim reiterates Adagene stock Buy rating on competitor shift By Investing.com

Guggenheim has reiterated a Buy rating and $10.00 price target for Adagene Inc. (NASDAQ: ADAG) following a competitor's strategic shift in colorectal cancer treatment. The competitor, Agenus Inc., discontinued a Phase 3 study to prioritize development in neoadjuvant colorectal ca

Tone
Positive 72/100
Event
Analyst action
Published
14 Jul 2026 11:11
Source
Investing.com Nigeria
Quartr Direct company coverage

Adagene (ADAG) Q4 2025 earnings summary

Adagene reported strong clinical progress for Muzastotug in Q4 2025, demonstrating notable response rates and median overall survival in clinical trials for MSS CRC, with favorable safety. The company's cash and cash equivalents stood at $74.5 million, providing a cash runway int

Tone
Neutral 50/100
Event
Earnings
Published
09 Jul 2026 12:40
Source
Quartr
Quartr Direct company coverage

Adagene (ADAG) H.C. Wainwright 27th Annual Global Investment Conference Summary

This article summarizes Adagene's presentation at the H.C. Wainwright 27th Annual Global Investment Conference, highlighting their next-generation antibody therapies for cancer. Key points include their proprietary NEObody, SAFEbody, and POWERbody platforms, strategic collaborati

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 00:41
Source
Quartr
Quartr Direct company coverage

Adagene (ADAG) Stifel 2026 Targeted Oncology Virtual Forum Summary

This article summarizes Adagene's presentation at the Stifel 2026 Targeted Oncology Virtual Forum, highlighting its SAFEbody masking technology for novel masked antibodies like ADG126 (muzastotug). It details ADG126's clinical efficacy and safety profile in combination therapies

Tone
Negative 42/100
Event
Market update
Published
09 Jul 2026 00:38
Source
Quartr
TradingView Direct company coverage

Enterprise value to EBITDA forward of Adagene Inc. – NASDAQ:ADAG

This article displays financial data for Adagene Inc. under the NASDAQ:ADAG ticker. Specifically, it focuses on the enterprise value to EBITDA forward metric, presenting its period, value, change, and percentage change. The content appears to be a stub or a data point from a fina

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 11:09
Source
TradingView
Stock Titan Direct company coverage

Adagene (ADAG) reports preliminary US$127.9M cash balance in June 2026 6-K

Adagene Inc. (ADAG) reported a preliminary, unaudited cash and cash equivalents balance of US$127.9 million as of June 30, 2026, through a Form 6-K SEC filing. The company emphasized that this figure is subject to finalization and is not a substitute for audited financial stateme

Tone
Neutral 50/100
Event
Balance sheet
Published
06 Jul 2026 11:40
Source
Stock Titan
TradingView Direct company coverage

Price to book forward of Adagene Inc. – NASDAQ:ADAG

This article presents the "Price to book forward" financial metric for Adagene Inc. (NASDAQ: ADAG). It appears to be a stub or a data-focused page from TradingView, indicating that specific numerical values for the metric were not populated or extracted in this instance. The cont

Tone
Neutral 50/100
Event
Market update
Published
06 Jul 2026 10:41
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBIT forward of Adagene Inc. – NASDAQ:ADAG

This article focuses on the "Enterprise value to EBIT forward" metric for Adagene Inc. (NASDAQ: ADAG). It provides a snapshot of this financial ratio for the company, accessible through TradingView's platform. The content is primarily a data label and a navigational entry point r

Tone
Neutral 50/100
Event
Market update
Published
06 Jul 2026 03:39
Source
TradingView
Finviz Direct company coverage

ADAG - Adagene Inc ADR Website Traffic and Mobile Apps Usage

This article provides comprehensive financial data, performance metrics, and news headlines for Adagene Inc. (ADAG). It includes details like market capitalization, P/E ratios, EPS, sales figures, institutional and insider ownership, and recent analyst ratings and company announc

Tone
Positive 64/100
Event
Earnings
Published
05 Jul 2026 22:40
Source
Finviz
TradingView Direct company coverage

Price to sales forward of Adagene Inc. – NASDAQ:ADAG

This article provides financial information for Adagene Inc. (NASDAQ: ADAG), specifically focusing on its forward price-to-sales ratio. It presents a quantitative value for this metric along with its percentage change over a specified period. The content appears to be a snapshot

Tone
Neutral 50/100
Event
Market update
Published
03 Jul 2026 15:40
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Adagene Inc. – NASDAQ:ADAG

This article provides the "Price to earnings forward" value for Adagene Inc. (NASDAQ: ADAG). It details the financial metric, along with navigation to other sections like overview, financials, news, and technicals on the TradingView platform for the company.

Tone
Neutral 50/100
Event
Earnings
Published
02 Jul 2026 22:10
Source
TradingView
TradingView Direct company coverage

Adagene, Inc. Sponsored ADR Actuals & Estimates (NASDAQ:ADAG)

This article provides an overview of Adagene Inc. (NASDAQ: ADAG) on TradingView, focusing on its financial actuals and estimates. It allows users to explore reported financial data and analyst estimates across income statement, balance sheet, cash flow statement, and valuation me

Tone
Neutral 50/100
Event
Analyst action
Published
26 Jun 2026 19:40
Source
TradingView
TradingView Direct company coverage

ADAG Forecast — Price Target — Prediction for 2027

This page provides a forecast and price target for Adagene Inc. (ADAG) on Nasdaq. According to 5 analysts, the 1-year price target for ADAG is 9.40. The page also mentions analyst ratings and details on EPS and Revenue metrics, while disclaiming that the information is not invest

Tone
Neutral 50/100
Event
Earnings
Published
25 Jun 2026 18:42
Source
TradingView
TradingKey Direct company coverage

Adagene Inc (ADAG) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Adagene Inc.'s (ADAG) dividend and stock split history. It states that Adagene Inc. has distributed 0.00 USD in dividends over the past five years and reports "No Data" for both dividend payments and stock splits, indicating a lack of such eve

Tone
Neutral 50/100
Event
Capital return
Published
18 Jun 2026 03:10
Source
TradingKey
Simply Wall Street Direct company coverage

Adagene (Nasdaq:ADAG) - Stock Analysis

Adagene Inc. (NasdaqGM:ADAG) is a clinical-stage biotechnology company focused on monoclonal antibody drugs for cancers. The company's stock is currently trading at US$3.94, with analysts setting a price target of US$9.40. Recent key developments include FDA Fast Track Designatio

Tone
Neutral 50/100
Event
Analyst action
Published
18 Jun 2026 03:10
Source
Simply Wall Street
TradingKey Direct company coverage

Adagene Inc (ADAG) Financial Health: Profitability & Balance Sheet Analysis

This article provides an analysis of Adagene Inc.'s (ADAG) financial health, focusing on profitability and balance sheet aspects. It reviews key financial indicators like cash and cash equivalents, total assets, total liabilities, free cash flow, total revenue, and operating prof

Tone
Neutral 50/100
Event
Earnings
Published
17 Jun 2026 21:40
Source
TradingKey
TradingKey Direct company coverage

Adagene Inc (ADAG) Institutional Confidence

This article provides details on the institutional confidence in Adagene Inc (ADAG), including current stock data such as market cap and price changes. It lists key institutional shareholders and their shareholdings, highlighting changes for some. The data presented aims to offer

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 21:39
Source
TradingKey
TradingKey Direct company coverage

Adagene Inc (ADAG) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Adagene Inc (ADAG), detailing its support, resistance, indicators, and moving averages. According to the analysis, Adagene Inc currently shows more sell signals than buy signals based on its technical indicators and moving averages. T

Tone
Negative 33/100
Event
Market update
Published
17 Jun 2026 21:39
Source
TradingKey
TradingKey Direct company coverage

Adagene Inc (ADAG) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Adagene Inc (ADAG), including analyst ratings and price targets. Based on 6 analysts, the stock has a "Buy" consensus with a target price of USD 11.345, representing a potential upside of 223.22%. The highest forecast is USD 21.07, a

Tone
Positive 72/100
Event
Earnings
Published
17 Jun 2026 21:39
Source
TradingKey
Market source Direct company coverage

Adagene (ADAG) Upgraded to Buy: Here's What You Should Know

Adagene Inc. (ADAG) has been upgraded to a Zacks Rank #2 (Buy), indicating a positive shift in its earnings outlook. This upgrade is driven by an upward trend in earnings estimates, which the Zacks system identifies as a powerful force influencing stock prices. The article sugges

Tone
Negative 42/100
Event
Analyst action
Published
05 Jun 2026 15:39
Source
Market source
Market source Direct company coverage

Are Medical Stocks Lagging Adagene (ADAG) This Year?

Adagene Inc. Sponsored ADR (ADAG) has significantly outperformed the Medical sector and its specific industry, Medical - Biomedical and Genetics, this year with a 100% year-to-date return. This strong performance is backed by a Zacks Rank of #2 (Buy) and a 37.3% increase in full-

Tone
Positive 75/100
Event
Market update
Published
02 Jun 2026 13:40
Source
Market source